Literature DB >> 32452542

Coronavirus 19 presenting with atypical Sweet's syndrome.

B Taşkın1,2, S Vural1, E Altuğ3, C Demirkesen4, E Kocatürk1, İ Çelebi5, B Ferhanoğlu6, S Alper1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32452542      PMCID: PMC7283742          DOI: 10.1111/jdv.16662

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   9.228


× No keyword cloud information.
Dear Editor, On 11 March 2020, the first case of the novel coronavirus 2019 disease (COVID‐19) was officially confirmed in Turkey. The disease continues to spread, and the number of patients has risen to 120 000 by the end of April. In this observation, we report an atypical presentation of COVID‐19 in a patient with indurated painful nodules. A 61‐year‐old woman with a 1‐week history of fever (axillary 38°C) and nodules on the cheek was admitted to the hospital with fatigue, arthralgia and myalgia. There were numerous erythematous nodules on the scalp, extremities and the trunk (Fig. 1). Minor aphthous ulcers were observed on the hard palate and buccal mucosa. The patient's history was unremarkable, and she was not using any medication. She did not have any respiratory symptoms.
Figure 1

(a) Multiple erythematous nodules on the face and (b) an infiltrated erythematous nodule on the knee.

(a) Multiple erythematous nodules on the face and (b) an infiltrated erythematous nodule on the knee. In laboratory work‐up, leucocytosis was detected 13.75 (4.1–11.1 K/UL). Neutrophils constituted 83% of the white blood cells 11.4 (0.0–0.5 K/UL). Lymphocyte count was 1.2 (1.2–5.8 K/UL). Eosinopenia was not detected. Acute‐phase reactants were significantly elevated [erythrocyte sedimentation rate: 101 (0–25 mm/h), C‐reactive protein level: 78.2 (<5.0 mg/L) and fibrinogen: 7.74 (1.8–3.6 g/L)]. The d‐dimer level was 1230 (<650 μg/L). The first SARS‐CoV‐2 RT‐PCR test from nasopharyngeal swab on admission was negative. Thorax computed tomography (CT) showed paramediastinal, peribronchoalveolar multifocal ground‐glass opacities in <30% of lung parenchyma. The patient was treated empirically with hydroxychloroquine, azithromycin and oseltamivir. To rule out other causes of fever, the patient underwent an abdominal CT. Abdominal CT did not reveal a mass lesion or a causative location for the fever. Skin biopsy from the right elbow revealed diffuse neutrophilic infiltration in the upper dermis and vascular proliferation with swollen endothelial cells and extravasated erythrocytes (Fig. 2a,b). In the lower dermis and at the periphery of the lobules of subcutaneous fat tissue, there were small granulomas, composed of epithelioid histiocytes and multinuclear giant cells, together with mild infiltration of histiocytes, lymphocytes and sparse neutrophils (Fig. 2c,d). The periodic acid–Schiff stain was negative. In the light of both clinical and histopathological features, the findings were interpreted as erythema nodosum‐like Sweet's syndrome (SS).
Figure 2

(a) Diffuse neutrophilic dermatitis together with panniculitis, prominent fibrinoid degeneration in the collagen fibres in the dermis and at the septum of the subcutaneous fat tissue was detected (HE ×4). (b) Oedema at the papillary dermis, neutrophilic infiltration, nuclear dust and extravasated erythrocytes (HE ×100). (c) In the lower dermis and at the periphery of the lobules of subcutaneous fat tissue, there were small granulomas, composed of epithelioid histiocytes and multinuclear giant cells (HE ×200). (d) Lymphocytes, histiocytes, sparse neutrophils and a few multinucleated giant cells at the periphery of the lobules in the subcutaneous fat tissue (HE ×200).

(a) Diffuse neutrophilic dermatitis together with panniculitis, prominent fibrinoid degeneration in the collagen fibres in the dermis and at the septum of the subcutaneous fat tissue was detected (HE ×4). (b) Oedema at the papillary dermis, neutrophilic infiltration, nuclear dust and extravasated erythrocytes (HE ×100). (c) In the lower dermis and at the periphery of the lobules of subcutaneous fat tissue, there were small granulomas, composed of epithelioid histiocytes and multinuclear giant cells (HE ×200). (d) Lymphocytes, histiocytes, sparse neutrophils and a few multinucleated giant cells at the periphery of the lobules in the subcutaneous fat tissue (HE ×200). The repeated SARS‐CoV‐2 RT‐PCR was positive. Due to prolonged fever despite the empirical treatment, a positron emission tomography scan was performed. It showed diffuse, bilateral parenchymal lung infiltration > 30%. Tocilizumab 400 mg intravenous infusion was given once, and favipiravir was started for five days. Fever subsided in 24 h. The skin lesions regressed with treatment. Acute febrile neutrophilic dermatosis (SS) is a rare reactive dermatosis associated with malignancies, inflammatory bowel disease, autoimmune disorders, drugs and infections. , Fever, myalgia, arthralgia and leucocytosis are the typical findings of SS. Oral mucosa involvement is an uncommon finding in Sweet’s syndrome (2–12%). , Oral ulcers are the most frequent mucosa involvement as in our patient. An immune reaction against the drugs, tumours or microbiological agents may start a cytokine cascade resulting in the onset of SS. In our case, no other cause except SARS‐CoV‐2 could be identified. The overlapping symptoms of SS with COVID‐19 complicated the diagnosis in this case. Recently, pseudo‐chilblain, atypical vesicular eruptions, urticarial lesions, maculopapular eruptions, and livedo or necrosis were reported as dermatological findings of COVID‐19. To our knowledge, this is the first reported case of SS associated with COVID‐19. The aberrant host response in COVID‐19 infection was proposed to be centred around neutrophils, and neutrophil extracellular traps were shown in the lung. In autopsy specimens, neutrophil infiltration in pulmonary capillaries, extravasation of neutrophils to alveolar space and capillaritis with fibrin deposition were shown. , The exaggerated neutrophilic response caused by the COVID‐19 in our patient may have triggered SS in the skin. Predominant cells in the inflammatory infiltration of oral aphthous ulcers are the neutrophils, compatible with the inflammation in SS. We want to draw attention to the overlapping symptoms of reactive neutrophilic dermatosis with COVID‐19 and the possibility of concurrent onset.

Conflict of interest

Dr. Taşkın, Dr. Vural, Dr. Altuğ, Dr. Demirkesen, Dr. Kocatürk, Dr. Çelebi, Dr. Ferhanoğlu and Dr. Alper have nothing to disclose.
  8 in total

1.  Bullous variant of Sweet's syndrome.

Authors:  Susanne Voelter-Mahlknecht; Jürgen Bauer; Gisela Metzler; Gerhard Fierlbeck; Gernot Rassner
Journal:  Int J Dermatol       Date:  2005-11       Impact factor: 2.736

Review 2.  Sweet's syndrome and cancer.

Authors:  P R Cohen; R Kurzrock
Journal:  Clin Dermatol       Date:  1993 Jan-Mar       Impact factor: 3.541

Review 3.  Sweet's syndrome (acute febrile neutrophilic dermatosis)

Authors:  P von den Driesch
Journal:  J Am Acad Dermatol       Date:  1994-10       Impact factor: 11.527

4.  Polymorphonuclear neutrophil function in recurrent aphthous stomatitis.

Authors:  D Wray; J Charon
Journal:  J Oral Pathol Med       Date:  1991-09       Impact factor: 4.253

5.  Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.

Authors:  Sharon E Fox; Aibek Akmatbekov; Jack L Harbert; Guang Li; J Quincy Brown; Richard S Vander Heide
Journal:  Lancet Respir Med       Date:  2020-05-27       Impact factor: 30.700

Review 6.  Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Authors:  Philip R Cohen
Journal:  Orphanet J Rare Dis       Date:  2007-07-26       Impact factor: 4.123

7.  Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.

Authors:  C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval
Journal:  Br J Dermatol       Date:  2020-06-10       Impact factor: 11.113

8.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps.

Authors:  Betsy J Barnes; Jose M Adrover; Amelia Baxter-Stoltzfus; Alain Borczuk; Jonathan Cools-Lartigue; James M Crawford; Juliane Daßler-Plenker; Philippe Guerci; Caroline Huynh; Jason S Knight; Massimo Loda; Mark R Looney; Florencia McAllister; Roni Rayes; Stephane Renaud; Simon Rousseau; Steven Salvatore; Robert E Schwartz; Jonathan D Spicer; Christian C Yost; Andrew Weber; Yu Zuo; Mikala Egeblad
Journal:  J Exp Med       Date:  2020-06-01       Impact factor: 17.579

  8 in total
  13 in total

Review 1.  The skin as a critical window in unveiling the pathophysiologic principles of COVID-19.

Authors:  Cynthia Magro; Gerard Nuovo; J Justin Mulvey; Jeffrey Laurence; Joanna Harp; A Neil Crowson
Journal:  Clin Dermatol       Date:  2021-07-22       Impact factor: 3.541

2.  SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics.

Authors:  Nicholas Hartog; William Faber; Austin Frisch; Jacob Bauss; Caleb P Bupp; Surender Rajasekaran; Jeremy W Prokop
Journal:  Expert Rev Proteomics       Date:  2021-04-05       Impact factor: 3.940

3.  Sweet's Syndrome Three Weeks after a Severe COVID-19 Infection: A Case Report.

Authors:  Simar Berro; Albane Calas; Pierre Sohier; Delphine Darbord; Nicolas Dupin
Journal:  Acta Derm Venereol       Date:  2021-06-30       Impact factor: 3.875

Review 4.  Cutaneous Manifestations in Confirmed COVID-19 Patients: A Systematic Review.

Authors:  Claudio Conforti; Caterina Dianzani; Marina Agozzino; Roberta Giuffrida; Giovanni Francesco Marangi; Nicola di Meo; Silviu-Horia Morariu; Paolo Persichetti; Francesco Segreto; Iris Zalaudek; Nicoleta Neagu
Journal:  Biology (Basel)       Date:  2020-12-05

Review 5.  Systemic and organ-specific immune-related manifestations of COVID-19.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-04-26       Impact factor: 20.543

6.  Oral Manifestations of COVID-19 in Hospitalized Patients: A Systematic Review.

Authors:  Giulia Orilisi; Marco Mascitti; Lucrezia Togni; Riccardo Monterubbianesi; Vincenzo Tosco; Flavia Vitiello; Andrea Santarelli; Angelo Putignano; Giovanna Orsini
Journal:  Int J Environ Res Public Health       Date:  2021-11-27       Impact factor: 3.390

7.  Relapsing symmetric livedo reticularis in a patient with COVID-19 infection.

Authors:  M Verheyden; M Grosber; J Gutermuth; B Velkeniers
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08-04       Impact factor: 9.228

Review 8.  Oral manifestations of COVID-19 disease: A review article.

Authors:  Behzad Iranmanesh; Maryam Khalili; Rezvan Amiri; Hamed Zartab; Mahin Aflatoonian
Journal:  Dermatol Ther       Date:  2020-12-13       Impact factor: 3.858

9.  Post-COVID-19 Unusual Inflammatory Syndromes Detected on 18F-FDG PET/CT Scan.

Authors:  Melvika Pereira; Divya Shivdasani; Debdip Roy; Rachita Rungta; Shreya Dang; Natasha Singh
Journal:  Clin Nucl Med       Date:  2022-04-01       Impact factor: 10.782

10.  Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study.

Authors:  Alba Català; Cristina Galván-Casas; Gregorio Carretero-Hernández; Pedro Rodríguez-Jiménez; Daniel Fernández-Nieto; Ana Rodríguez-Villa; Íñigo Navarro-Fernández; Ricardo Ruiz-Villaverde; Daniel Falkenhain-López; Mar Llamas-Velasco; Lucía Carnero-Gonzalez; Juan García-Gavin; Ofelia Baniandrés; Carlos González-Cruz; Víctor Morillas-Lahuerta; Xavier Cubiró; Ignasi Figueras; Gerald Selda-Enriquez; Xavier Fustà-Novell; Mónica Roncero-Riesco; Patrícia Burgos-Blasco; Jorge Romaní; Joaquim Solà-Ortigosa; Ignacio García-Doval
Journal:  Dermatol Ther       Date:  2020-09-09       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.